Dose selection of siltuximab for multicentric Castleman's disease

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 5, 2015, Pages 1037-1045

  Mayer, Christina L ^a   Xie, Lanyi ^a   Bandekar, Rajesh ^a   Qi, Ming ^a   Van De Velde, Helgi ^b   Reddy, Manjula ^a   Qin, Xiang ^a   Davis, Hugh M ^a   Puchalski, Thomas A ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Dose selection; Modeling; Pharmacodynamics; Pharmacokinetics; Siltuximab

Indexed keywords

ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; SILTUXIMAB;

AGED; BIOLOGICAL MODEL; BLOOD; DOSE RESPONSE; GIANT LYMPH NODE HYPERPLASIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MODELS, BIOLOGICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84938677947     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2720-0     Document Type: Article

References (38)

1. Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621-636
2. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (1998) Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 334:297-314
3. Gadient RA, Otten UH (1997) Interleukin-6 (IL-6) - a molecule with both beneficial and destructive potentials. Prog Neurobiol 52:379-390
4. Ganz T, Nemeth E (2009) Iron sequestration and anemia of inflammation. Semin Hematol 46:387-393
5. Karin M (2006) Nuclear factor-κB in cancer development and progression. Nature 441:431-436
6. Grivennikov S, Karin M (2008) Autocrine IL-6 signaling: a key event in tumorigenesis? Cancer Cell 13:7-9
7. Kishimoto T (1989) The biology of interleukin-6. Blood 74:1-10
8. Klein B, Zhang XG, Lu ZY, Bataille R (1995) Interleukin-6 in human multiple myeloma. Blood 85:863-872
9. Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S, Anderson KC (2000) SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 275:27845-27850
10. Kurzrock R (2001) Cytokine deregulation in cancer. Biomed Pharmacother 55:543-547
11. Kurzrock R, Redman J, Cabanillas F, Jones D, Rothberg J, Talpaz M (1993) Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms. Cancer Res 53:2118-2122
12. Casper C (2005) The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 129:3-17
13. van Rhee F, Fayad L, Voorhees P, Furman R, Lonial S, Borghaei H, Sokol L, Crawford J, Cornfeld M, Qi M, Qin X, Herring J, Casper C, Kurzrock R (2010) Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 28:3701-3708
14. Katsume A, Miyai T, Suzuki H, Moriguchi Y, Kawata H, Tatsumi T, Suematsu S, Kishimoto T, Ohsugi Y (1997) Interleukin-6 overexpression cannot generate serious disorders in severe combined immunodeficiency mice. Clin Immunol Immunopathol 82:117-124
15. Katsume A, Saito H, Yamada Y, Yorozu K, Ueda O, Akamatsu K, Nishimoto N, Kishimoto T, Yoshizaki K, Ohsugi Y (2002) Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine 20:304-311
16. Anderson KC, Kyle RA, Dalton WS, Landowski T, Shain K, Jove R, Hazlehurst L, Berenson J (2000) Multiple myeloma: new insights and therapeutic approaches. Hematology Am Soc Hematol Educ Program 2000:147-165
17. Seideman J, Peritt D (2002) A novel monoclonal antibody screening method using the Luminex-100 microsphere system. J Immunol Methods 267:165-171
18. Wang W, Wang X, Doddareddy R, Fink D, McIntosh T, Davis HM, Zhou H (2014) Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys. AAPS J 16:129-139
19. Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9:4653-4665
20. van Zaanen HC, Lokhorst HM, Aarden LA, Rensink HJ, Warnaar SO, van der Lelie J, van Oers MH (1998) Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study. Br J Haematol 102:783-790
21. Coventry BJ, Ashdown ML, Quinn MA, Markovic SN, Yatomi-Clarke SL, Robinson AP (2009) CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool? J Transl Med 7:102
22. Legouffe E, Rodriguez C, Picot MC, Richard B, Klein B, Rossi JF, Commes T (1998) C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma 31:351-357
23. Pelliniemi TT, Irjala K, Mattila K, Pulkki K, Rajamaki A, Tienhaara A, Laakso M, Lahtinen R, for the Finnish Leukemia Group (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood 85:765-771
24. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, Kishimoto T, Yoshizaki K (2000) Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95:56-61
25. Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F (2013) A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res 19:3659-3670
26. Rossi JF, Negrier S, James ND, Kocak I, Hawkins R, Davis H, Prabhakar U, Qin X, Mulders P, Berns B (2010) A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer. Br J Cancer 103:1154-1162
27. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM (2010) Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 16:1652-1661
28. Xu C, Han C, Marini J, Ford J, Marciniak S, Lopez M Jr, Frederick B, de Vries D, Bandekar R, Davis HM, Zhou H, Puchalski T (2014) A phase 1, randomized study to assess the pharmacokinetic comparability of siltuximab derived from two different cell lines in healthy subjects. Clin Pharmacol Drug Dev 3(4):328-334
29. Marshall JL (2012) Maximum-tolerated dose, optimum biologic dose, or optimum clinical value: dosing determination of cancer therapies. J Clin Oncol 30:2815-2816
30. Takimoto CH, Ng CM, Puchalski T (2011) Pharmacokinetics and pharmacodynamics. In: DeVita VTJ, Lawrence TS, Rosenberg SA (eds) DeVita, Hellman, and Rosenberg's cancer: principles & practice of oncology, 9th edn. Lippincott Williams & Wilkins, Philadelphia, pp 360-369
31. Thongtang N, Diffenderfer MR, Ooi EM, Asztalos BF, Dolnikowski GG, Lamon-Fava S, Schaefer EJ (2013) Effects of atorvastatin on human C-reactive protein metabolism. Atherosclerosis 226:466-470
32. Mauger JF, Levesque J, Paradis ME, Bergeron N, Tchernof A, Couture P, Lamarche B (2008) Intravascular kinetics of C-reactive protein and their relationships with features of the metabolic syndrome. J Clin Endocrinol Metab 93:3158-3164
33. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW (1999) C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978
34. Husain T, Kim D (2002) C-reactive protein and erythrocyte sedimentation rate in orthopaedics. Univ Pa Orthop J 15:13-16
35. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD, Pepys MB (2000) Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 46:934-938
36. van Rhee F, Wong RS, Munshi N, Rossi J-F, Ke X-Y, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho S-G, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Reddy M, van de Velde H, Vermeulen J, Casper C (2014) Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol 15:966-974
37. Wong R, Casper C, Munshi N, Ke X, Fosså A, Simpson D, Capra M, Liu T, Hsieh RK, Goh YT, Zhu J, Cho S-G, Ren H, Cavet J, Bandekar R, Rothman M, Puchalski TA, Chaturvedi S, van de Velde H, Vermeulen J, van Rhee F (2013) A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman's disease. Abstract presented at: 55th American Society of Hematology annual meeting and exposition, 9 Dec 2013, New Orleans, LA
38. Casper C, Chaturvedi S, Munshi N, Wong R, Qi M, Schaffer M, Bandekar R, Huang Y, Hall B, Vermeulen J, Reddy M, van Rhee F (2014) Inflammatory and anaemia-related markers in a phase 2, randomised, double-blind, placebo-controlled study of siltuximab (anti-IL-6 monoclonal antibody) in multicentric Castleman's disease patients. Poster presented at: 19th congress of the European Hematology Association; 12-15 June 2014, Milan, Italy